Bjork Elisabeth reported option exercise involving 10,000 derivative units of Pharvaris N.V. at $0.00 for $0 on May 20, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed May 22, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
10,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
11,000Direct
Trade date
May 20, 2026Option exercise
Filed
May 22, 2026, 2:54 PM ET2-day reporting delay
Accession
0001193125-26-236432Code M · Transaction 384137
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 20, 2026Sell10,000$29.32−$293,166Trade 384136
May 20, 2026Option exercise10,000$8.05$80,500Trade 384135
3 transaction rows in this filing. Joint filers share the same rows.

PHVS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PHVS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −2.4%1w ago +11%1d ago −2.5%
Returns since7d +1.6%30d +11%90d +23%180d1y

Footnotes in full

F1: This is a scheduled exercise and sale from 10b5-1 trading plan. F2: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $29.03 to $29.61. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3: 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.